Pharmaceutical compositions comprising an hiv envelope protein and cd4
OwnerPaolo Lusso, Samuele Burasteroinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerPaolo Lusso, Samuele Burasteroinventors
Estimating the term…
Pharmaceutical composition for treating/preventing HIV comprising (i) a polynucleotide encoding HIV envelope protein and (ii) a polynucleotide encoding CD4 receptor protein or; (i) a polynucleotide encoding HIV envelope protein and (ii) a CD4 receptor protein or; a fixed cell expressing an HIV envelope protein complexed with a CD4 receptor protein. Also disclosed are pharmaceutical compositions for treating/preventing HIV comprising an antibody immunospecific for a fixed cell expressing an HIV envelope protein complex with a CD4 receptor protein. The binding of the CD4 to the HIV envelope protein, i.e. gp120, exposes hidden epitopes that may be used as targets in immunotherapy; the presentation of the gp120 and CD4 in the present forms is said to overcome problems with prior art soluble gp120-CD4 complexes.
A pharmaceutical composition comprising (i) a polynucleotide encoding an HIV envelope protein and (ii) a polynucleotide encoding a CD4 receptor.
A pharmaceutical composition comprising (i) a polynucleotide encoding an HIV envelope protein and (ii) a CD4 receptor.
A fixed cell wherein said cell expresses an HIV envelope protein and further wherein said envelope protein is complexed with a CD4 receptor.
A hybridoma cell line having the identifying characteristics of the cell line deposited with the Advanced Biotechnology Center Inter Lab Cell Line Collection (CBA ICLB) wherein said hybridoma produces DB-81.
Dependencies are inferred from the claim text.